An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia

Gertjan J L Kaspers, Denise Niewerth, Bram A J Wilhelm, Peggy Scholte-van Houtem, Marta Lopez-Yurda, Johannes Berkhof, Jacqueline Cloos, Valerie de Haas, Ron A Mathôt, Andishe Attarbaschi, André Baruchel, Eveline S de Bont, Franca Fagioli, Claudia Rössig, Thomas Klingebiel, Barbara De Moerloose, Brigitte Nelken, Giuseppe Palumbo, Dirk Reinhardt, Pierre-Simon RohrlichPauline Simon, Arend von Stackelberg, Christian Michel Zwaan

Research output: Contribution to journalArticle

Abstract

This trial explored the efficacy of re-induction chemotherapy including bortezomib in paediatric relapsed/refractory acute lymphoblastic leukaemia. Patients were randomized 1:1 to bortezomib (1.3 mg/m2 /dose) administered early or late to a dexamethasone and vincristine backbone. Both groups did not differ regarding peripheral blast count on day 8, the primary endpoint. After cycle 1, 8 of 25 (32%) patients achieved complete remission with incomplete blood count recovery, 7 (28%) a partial remission and 10 had treatment failure. Most common grade 3-4 toxicities were febrile neutropenia (31%) and pain (17%). Bortezomib was safely combined with vincristine. Bortezomib rarely penetrated the cerebrospinal fluid.

Original languageEnglish
Pages (from-to)523-527
Number of pages5
JournalBritish Journal of Haematology
Volume181
Issue number4
DOIs
Publication statusPublished - May 2018

Fingerprint Dive into the research topics of 'An effective modestly intensive re-induction regimen with bortezomib in relapsed or refractory paediatric acute lymphoblastic leukaemia'. Together they form a unique fingerprint.

Cite this